Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis

Suppressive myeloid cells can contribute to immunotherapy resistance, but their role in response to checkpoint inhibition (CPI) in anti-PD-1 refractory cancers, such as biliary tract cancer (BTC), remains elusive. We use multiplexed single-cell transcriptomic and epitope sequencing to profile greater than 200,000 peripheral blood mononuclear cells from advanced BTC patients (n = 9) and matched healthy donors (n = 8). Following anti-PD-1 treatment, CD14(+) monocytes expressing high levels of immunosuppressive cytokines and chemotactic molecules (CD14(CTX)) increase in the circulation of patients with BTC tumors that are CPI resistant. CD14(CTX) can directly suppress CD4(+) T cells and induce SOCS3 expression in CD4(+) T cells, rendering them functionally unresponsive. The CD14(CTX) gene signature associates with worse survival in patients with BTC as well as in other anti-PD-1 refractory cancers. These results demonstrate that monocytes arising after anti-PD-1 treatment can induce T cell paralysis as a distinct mode of tumor-mediated immunosuppression leading to CPI resistance.